News

Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)

(June 12, 2018) – Sunovion Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for apomorphine sublingual film (APL-130277) to treat motor fluctuations experienced by people living with Parkinson’s disease. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is January 29, 2019. Read more

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2018 The Parkinson Alliance. All rights reserved.